发明名称 |
C-linked hydroxamic acid derivatives useful as antibacterial agents |
摘要 |
The present invention is directed to a new class of hydroxamic acid derivatives of Formula I,;
wherein the variables G, T, D, L, A, X, R1 and R2 are as described hereinabove, and their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. |
申请公布号 |
US8853258(B2) |
申请公布日期 |
2014.10.07 |
申请号 |
US201013501776 |
申请日期 |
2010.10.04 |
申请人 |
Pfizer Inc. |
发明人 |
Brown Matthew Frank;Marfat Anthony;Melnick Michael Joseph;Reilly Usa |
分类号 |
A61K31/382;A61K31/47;A61K31/661;C07D215/06;C07C317/44;C07D231/56;C07F9/12;C07C323/65;C07C317/46;C07D213/56;C07C317/48;C07D263/08;C07D295/03;C07D263/20;C07D335/02;C07D213/30 |
主分类号 |
A61K31/382 |
代理机构 |
|
代理人 |
Wichtowski John A. |
主权项 |
1. A compound selected from the group consisting of
(2R)-4-(4′-cyanobiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)-4-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; 4-(2′-fluorobiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; N-hydroxy-4-(4′-methoxybiphenyl-4-yl)-2-methyl-2-(methylsulfonyl)butanamide; N-hydroxy-4-[4-(1H-indol-5-yl)phenyl]-2-methyl-2-(methylsulfonyl)butanamide; 4-[4-(5-cyano-2-thienyl)phenyl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)-4-[4-(1,3-benzodioxol-5-yl)phenyl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)—N-hydroxy-4-[4-(1H-indol-2-yl)phenyl]-2-methyl-2-(methylsulfonyl)butanamide; (2R)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; 4-(2,4′-difluorobiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)-4-(4′-glycoloylbiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)—N-hydroxy-4-[4-(6-methoxypyridin-3-yl)phenyl]-2-methyl-2-(methylsulfonyl)butanamide; 4-[4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; 4-(4′-cyano-3-fluorobiphenyl-4-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; N-hydroxy-4-[4′-(4-hydroxybutoxy)biphenyl-4-yl]-2-methyl-2-(methylsulfonyl)butanamide; (2R)—N-hydroxy-4-(4′-hydroxybiphenyl-4-yl)-2-methyl-2-(methylsulfonyl)butanamide; 4-[4-(benzyloxy)phenyl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; (2R)—N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[4′-(3-morpholin-4-ylpropoxy)biphenyl-4-yl]butanamide; 4-[3-fluoro-4-(6-methoxypyridin-3-yl)phenyl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; 4-(4-cyclohex-1-en-1-ylphenyl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; N-hydroxy-2-methyl-2-(methylsulfonyl)-4-[4-(4-methyl-2-thienyl)phenyl]butanamide; 4-(3-fluoro-4-quinolin-6-ylphenyl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; and 4′-[(3R)-4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl]biphenyl-4-yl dihydrogen phosphate; or a pharmaceutically acceptable salt thereof. |
地址 |
New York NY US |